Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; stearic acid; microcrystalline cellulose; iron oxide red; hypromellose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.47 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; magnesium stearate; purified talc; hypromellose; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.74 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; croscarmellose sodium; macrogol 400; hypromellose; titanium dioxide; microcrystalline cellulose; magnesium stearate - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; microcrystalline cellulose - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - modafinil -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.